Turkey Regulatory Brief / Archive
Amendment to the Electricity Market Balancing and Settlement Regulation
Type Regulation Published 21 Oct 2026
Amends Article 132/E(4)(c) so that a market participant that fails to provide sufficient collateral after a collateral call, or that remains in default and does not pay its default debt before completing collateral, cannot continue activities in bilateral contracts, the forward market, the day-ahead market and the intraday market. Directly relevant to electricity market participants and traders operating in Turkey.
Original title: Elektrik Piyasası Dengeleme ve Uzlaştırma Yönetmeliğinde Değişiklik Yapılmasına Dair Yönetmelik
Read the official notice
Summary written with AI assistance from the official text; check the source before acting.
Get items like this first
What changed in Turkish law today, from the Official Gazette, in clear English: regulations, decrees and communiqués that affect business.
Related
Decision Published 21 Oct 2026
The Nuclear Regulatory Authority (NDK) Board sets out the required content of the Nuclear Material Accountancy and Control Programme that licensed nuclear facilities must prepare and submit during authorisation stages. It covers facility nuclear safeguards organisation, material balance areas, measurement methods, transfers, physical inventory, unusual-event reporting, Additional Protocol reporting and internal audits. It mainly affects operators and licensed persons of nuclear facilities in Turkey.
Decision Published 21 Oct 2026
The Energy Market Regulatory Board adds a new ground to the collateral rules for energy market participants: an outstanding debt arising from unpaid invoice amounts for billing periods whose payment due date has passed. Market participants with overdue energy invoices may be affected by collateral requirements. The amendment takes effect on the date of publication.
Regulation Published 21 Oct 2026
Amends the Turkish Cancer Institute Regulation under the Turkish Health Institutes Presidency: it removes some provisions, restructures the institute so it consists of the Institute Presidency, scientific boards and other units, and replaces the cancer-institute scientific board with four named scientific boards (epidemiology and preventive oncology, clinical oncology, basic oncology and genetics, tumour immunology and cell therapies). Board membership, terms and meeting rules are also updated. The change mainly affects the institute's internal governance and its scientific advisory bodies rather than private businesses.
Regulation Published 21 Oct 2026
Amends the institute's organisational regulation by removing one unit, restructuring the Scientific Boards into two boards covering newborn/child/adolescent health and maternal/perinatal health, and abolishing one article. It also adds a new article on data governance, confidentiality and ethics, requiring ethics committee approval before research involving human participants, biological material or health data, and takes effect on publication.
Regulation Published 21 Oct 2026
Amends the Human Medicinal Products Manufacturing Facilities Regulation by adding definitions for aromatherapeutic products, traditional herbal medicinal products, hemp-derived products, medical foods and medicinal herbal teas, and extends the scope of the manufacturing rules to cover these product types. It also replaces 'inspectors' with 'müfettiş' (inspector) terminology, lets officers with at least two years as responsible physician at licensed regional blood centres serve as responsible pharmacist at plasma-derived product plants, and takes effect on publication.